Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-10-06
2011-11-22
Aeder, Sean (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S184100
Reexamination Certificate
active
08063183
ABSTRACT:
In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
REFERENCES:
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5624899 (1997-04-01), Bennett
patent: 5635177 (1997-06-01), Bennett
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5795734 (1998-08-01), Flanagan et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5864020 (1999-01-01), Bennett
patent: 6015711 (2000-01-01), Olson et al.
patent: 6303769 (2001-10-01), Cerretti
patent: 6413730 (2002-07-01), Holland et al.
patent: 6440954 (2002-08-01), Haber et al.
patent: 6479459 (2002-11-01), Cerretti
patent: 6492140 (2002-12-01), Cerretti
patent: 6514497 (2003-02-01), Briskin et al.
patent: 6579683 (2003-06-01), Wang et al.
patent: 6864227 (2005-03-01), Wang et al.
patent: 6887674 (2005-05-01), Wang et al.
patent: 6916625 (2005-07-01), Wang et al.
patent: 2002/0086819 (2002-07-01), Drummond et al.
patent: 2002/0136726 (2002-09-01), Anderson et al.
patent: 2002/0146420 (2002-10-01), Bennett
patent: 2004/0110150 (2004-06-01), Koller et al.
patent: 2004/0234520 (2004-11-01), Aguet et al.
patent: 2004/0247592 (2004-12-01), Roifman et al.
patent: 2005/0049176 (2005-03-01), Kiener et al.
patent: 2005/0084873 (2005-04-01), Krasnoperov et al.
patent: 2005/0164965 (2005-07-01), Reddy et al.
patent: 2005/0187154 (2005-08-01), Kahn et al.
patent: 2005/0204412 (2005-09-01), Wang et al.
patent: 2006/0035328 (2006-02-01), Wang et al.
patent: 2006/0204512 (2006-09-01), Krasnoperov et al.
patent: 2006/0241027 (2006-10-01), Hauser et al.
patent: 2007/0207952 (2007-09-01), Silva et al.
patent: 0 442 724 (1991-08-01), None
patent: 0 633 315 (1995-01-01), None
patent: 0999 278 (2000-05-01), None
patent: WO 93/00425 (1993-01-01), None
patent: WO-93/15201 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11020 (1994-05-01), None
patent: WO-95/27061 (1995-10-01), None
patent: WO 95/27061 (1995-10-01), None
patent: WO-96/01839 (1996-01-01), None
patent: WO-96/02645 (1996-02-01), None
patent: WO 96/03043 (1996-02-01), None
patent: WO 96/09384 (1996-03-01), None
patent: WO 96/13518 (1996-05-01), None
patent: WO 96/23000 (1996-08-01), None
patent: WO-96/26958 (1996-09-01), None
patent: WO 96/36713 (1996-11-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/23629 (1997-07-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO-98/01548 (1998-01-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO-98/45708 (1998-10-01), None
patent: WO-99/08696 (1999-02-01), None
patent: WO 99/17796 (1999-04-01), None
patent: WO 99/52541 (1999-10-01), None
patent: WO-00/24413 (2000-05-01), None
patent: WO-00/30673 (2000-06-01), None
patent: WO 01/49743 (2001-07-01), None
patent: WO 01/81377 (2001-11-01), None
patent: WO-02/11785 (2002-02-01), None
patent: WO-02/26827 (2002-04-01), None
patent: WO-02/058538 (2002-08-01), None
patent: WO-02/061055 (2002-08-01), None
patent: WO-02/079382 (2002-10-01), None
patent: WO-02/102854 (2002-12-01), None
patent: WO-02/102972 (2002-12-01), None
patent: WO-02/102973 (2002-12-01), None
patent: WO 03/000113 (2003-01-01), None
patent: WO-03/004057 (2003-01-01), None
patent: WO 03/004057 (2003-01-01), None
patent: WO 03/094859 (2003-11-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 2004/020468 (2004-03-01), None
patent: WO-2004/024773 (2004-03-01), None
patent: WO-2004/080425 (2004-09-01), None
patent: WO 2004/091375 (2004-10-01), None
patent: WO-2005/048917 (2005-06-01), None
patent: WO 2005/051307 (2005-06-01), None
patent: WO 2005/090406 (2005-09-01), None
Sequence comparison.
Kiessig et al (Electrophoresis, 2001, 22:1428-1435).
Miki et al (JBC, 1994, 269(8): 5489-5492).
Bennett et al (JBC, 1991, 266:23060-23067).
Perrin et al (JBC, 2001, 276(34): 31528-31534).
Noren et al (Nature Cell Bio, 2006, 8:815-825).
Bennett et al (WO 95/27061; Oct. 12, 1995).
Kitamura et al., “Chemical Engineering of the Monoclonal Antibody A7 by Polyethylene Glycol for Targeting Cancer Chemotherapy,”Cancer Research, 51:4310-4315 (1991).
Dermer, G., “Another Anniversary for the War on Cancer,”Bio/Technology, 12:320 (1994).
Freshney, R. Ian, Culture of Animal Cells: A Manual of Basic Technique, Alan R. Liss, Inc. (1983).
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science, 278:1041-1042 (1997).
Carbone, M., et al., “The pathogenesis of mesothelioma,” Semin. Oncol., 29(1):2-17 (2002).
Gerety, S.S., et al., “Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development,” Mol. Cell, 4:403-414 (1999).
Wang, H.U., et al., “Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4,” Cell, 93:741-753 (1998).
Shin, D., et al., “Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization,” Dev. Biol., 230:139-150 (2001).
Kiyokawa, E., et al., “Overexpression of ERK, an EPH family receptor-protein tyrosine kinase, in various human tumors,” Cancer Res., 54:3645-3650 (1994).
Hirai, H., “A novel putative tyrosine kinase receptor encoded by the eph gene,” Science, 238:1717-1720 (1987).
Pasquale, E.B., “The Eph family of receptors,” Curr. Opin. Cell Biol., 9:608-619 (1997).
Stephenson, S.A., “Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer,” BMC Mol. Biol., 2:15 (2001).
Berclaz, G., et al., “Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma,” Ann. Oncol., 14:220-226 (2003).
Takai, N., et al., “Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer,” Oncol. Rep., 8:567-573 (2001).
Steinle, J.J., et al., “Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway,” J. Biol. Chem., 277(46):43830-5 (Nov. 15, 2002) (Epub Sep. 13, 2002).
Munarini, N., “Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase,” J. Cell. Sci., 115(Pt 1):25-37 (Jan. 1, 2002).
Gill, P.S., et al., “Epidemic (AIDS-related) Kaposi's sarcoma: Epidemiology pathogenesis and treatment,” AIDS Updates, (7) 1-11 (1994).
Adams, R.H., et al., “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis,” Genes Dev., 13:295-306 (1999).
Gerety, S.S., et al., “Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development,” Mol. Cell, 4:403-414 (1999).
Wang, H.U., et al., “Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4,” Cell 93:741-753 (1998).
Shin, D., et al., “Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization,” Dev. Biol. 230:139-150 (2001).
Sinha, U.K., et al., “Expression of EphB4 in head and neck squamous cell carcinoma,” ENT J 82:721-723 (2003).
Hamada, K., et al., “Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells,” Arterioscler. Thromb. Vasc. Biol., 23:190-197 (2003).
Fuller
Gill Parkash
Kertesz Nathalie
Krasnoperov Valery
Reddy Ramachandra
Zozulya Sergey
Aeder Sean
Ropes & Gray LLP
VasGene Therapeutics, Inc.
LandOfFree
Polypeptide compounds for inhibiting angiogenesis and tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide compounds for inhibiting angiogenesis and tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide compounds for inhibiting angiogenesis and tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279416